Pronova BioPharma ASA said it plans to use an alginate-based capsule technology in the future development of its lead product, Omacor/Lovaza, as well as other products in its pipeline in what appears to be a move to protect its patent position.
Pronova BioPharma ASA said it plans to use an alginate-based capsule technology in the future development of its lead product, Omacor/Lovaza, as well as other products in its pipeline in what appears to be a move to protect its patent position.